If you wish to receive Everest Medicines Limited information by email, please choose your options for email notification, enter your email address and information below and click "Submit".
2021-01-18
VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON AMENDED AGREEMENT WITH SPERO THERAPEUTICS
2021-01-06
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 DECEMBER 2020
2021-01-06
VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON APPROVAL OF CLINICAL TRIAL APPLICATION BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION FOR PHASE 3 REGISTRATION TRIAL OF SACITUZUMAB GOVITECAN-HZIY FOR METASTATIC UROTHELIAL CANCER
2021-01-06
VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON SUBMISSION OF NEW DRUG APPLICATION IN SINGAPORE FOR SACITUZUMAB GOVITECAN-HZIY FOR THE TREATMENT OF METASTATIC TRIPLE-NEGATIVE BREAST CANCER
2020-12-22
CHANGE IN DIRECTORS OR OF IMPORTANT EXECUTIVE FUNCTIONS OR RESPONSIBILITIES APPOINTMENT OF NON-EXECUTIVE DIRECTOR
2020-12-09
VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON FIRST PATIENT DOSED IN PHASE 3 REGISTRATION ASIAN STUDY OF TRODELVY (SACITUZUMAB GOVITECAN) FOR HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE METASTATIC BREAST CANCER
2020-12-04
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 NOVEMBER 2020
2020-12-04
(REVISED) MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED OCTOBER 31, 2020
2020-12-02
VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE ON RECOMMENDED BREAKTHROUGH THERAPY DESIGNATION FOR NEFECON FOR THE TREATMENT OF IGA NEPHROPATHY
2020-11-10
VOLUNTARY ANNOUNCEMENT - BUSINESS UPDATE ON LICENSING PARTNER CALLIDITAS THERAPEUTICS REPORTING TOPLINE RESULTS FROM PIVOTAL PHASE 3 NEFIGARD TRIAL
